

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace prior versions and listings of claims in the application:

Listing of claims:

Claims 1, 5, 7, 11, 13, 14, 16-18 have been amended as follows:

Underlines indicate insertions and ~~strikeouts~~ indicate deletions. Claims 4, 12 and 20-21 have been cancelled.

Claim 1. (currently amended) A method for generating an established cell line which produces enables the replication of complete and infectious hepatitis C virus (HCV) comprising transforming peripheral blood mononuclear cells (PBMCs) which produce HCV with Epstein Barr virus (EBV).

Claim 2. (original) The method of claim 1, wherein said cells producing HCV, are in a peripheral blood lymphocyte (PBL) fraction of said PBMCs.

Claim 3. (original) The method of claim 2, wherein said cells producing HCV, are B-cells.

Claim 4. (cancelled) ~~The method of any one of claims 1 to 3, wherein said HCV produced by said established cell line enables the replication of complete and infectious HCV PBMCs are naïve cells.~~

Claim 5. (currently amended) A method for producing HCV *in vitro* comprising:
a) generating an established cell line which produces enables the replication of complete and infectious hepatitis C virus (HCV) comprising transforming a B-cell which produces HCV, with Epstein Barr virus (EBV);

b) growing the EBV-immortalized B-cell obtained in a) in culture under conditions enabling complete and infectious HCV production.

Claim 6. (original) The method of claim 5, wherein conditions in b) comprise a stimulation of said EBV-immortalized B-cell to produce HCV.

Claim 7. (currently amended) The method of claim 5-~~or 6~~, wherein said B-cell is present in a PBMC or PBL.

BEST AVAILABLE COPY

Claim 8. (original) The method of claim 7, wherein said PBMC or PBL fraction is obtained from a HCV positive patient which is immunosuppressed.

Claim 9. (original) The method of claim 8, wherein said immunosuppression is due to injection drug use of said patient.

Claim 10. (original) The method of claim 7, wherein said PBMC or PBL fraction is obtained from a HCV positive patient which has not been treated with interleukin.

Claim 11. (currently amended) The method of ~~any one of~~ claims 5 ~~to 10~~, further comprising a co-cultivation of said EBV-immortalized B-cell, which is stimulated to produce HCV in the presence of monocyte-derived dendritic cells (DCs).

Claim 12. (cancelled) ~~The method of any one of claims 6 to 11, wherein said stimulating is carried out using an HCV replication activating inducing amount of at least one mitogen.~~

Claim 13. (currently amended) An EBV-established B-cell line capable of replicating complete and infectious HCV obtained by the method of claim 1.

Claim 14. (currently amended) A cell-based *in vitro* replication system for HCV comprising an EBV-transformed B-cell capable of replicating complete and infectious HCV, and a second cell population having HCV tropism and in which robust HCV replication occurs, so that under appropriate culture conditions said second cell population can become infected by said infectious HCV produced by said EBV-transformed B-cell, and wherein said second cell population is a naïve cell population.

Claim 15. (original) The cell-based replication system of claim 14, further comprising appropriate culture media reagents conditions enabling infection of said second cell population.

Claim 16. (currently amended) The cell-based replication system of claim 14 ~~or 15~~, wherein said second cell population is peripheral blood lymphocytes (PBLs).

Claim 17. (currently amended) The cell-based replication system of claim 14, ~~15 or 16~~, wherein said second cell population is a cell line.

BEST AVAILABLE COPY

Claim 18. (currently amended) An assay for screening a test agent and selecting an agent which possesses anti-HCV activity, comprising:

- a) ~~growing a EBV-immortalized cell line which produces HCV, or culturing said EBV-immortalized cell line with a second cell population using said cell-based in vitro replication system of claim 14 so as produce HCV from said second cell population;~~
and
- b) assaying a biological function of said HCV produced from said cell line or said cell population.

Claim 19. (original) The assay of claim 18, wherein said biological function is selected from the group consisting of binding to a cellular receptor of HCV, replication, translation, assembly, and infectivity.

Claim 20. (cancelled) ~~A method for identifying, from a library of compounds, a compound with anti-HCV activity, comprising:~~

- ~~a) providing a screening assay according to claim 18 or 19;~~
- ~~b) contacting said screening assay with at least one compound from said library; and~~
- ~~c) detecting if said at least one compound inhibits a biological activity of HCV;~~
~~wherein a test compound which inhibits said biological activity is a compound with said anti-HCV activity.~~

Claim 21. (cancelled) ~~The method of claim 20, wherein the test compound with said anti-HCV activity is further modified by combinatorial or medicinal chemistry to provide further analogs of said test compound also having said therapeutic effect.~~

BEST AVAILABLE COPY